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ABSTRACT
Background: Pranlukast and Montelukast are Cysteinyl leukotriene receptor antagonists with almost the
same pharmacological activity. However, I will describe a case in which these drugs showed different therapeu-
tic effects on clinical symptoms during the daytime and eosinophilic inflammation in the peripheral airway.
Methods: A 70-year-old male patient with non-atopic bronchial asthma who was treated with 400 μgday of
Budesonide TurbuhalerⓇ (BUD-TH) changed from Pranlukast (225 mg, twice daily) to Montelukast (10 mg, one
tablet before sleeping), resulting in worsening clinical symptoms consisting of sputum and cough in the day-
time, mainly at lunch time. Due to the fact that the symptoms did not improve sufficiently, instead of increasing
the dose of BUD-TH, we investigated the clinical symptoms and pulmonary functions as well as measured the
mean eosinophil count, eosinophil cationic protein (ECP) and eotaxin in the hypertonic saline-induced sputum
prior to administration of Pranlukast, and 4 and 8 weeks after the re-administration of Pranlukast from Montelu-
kast.
Results: Following the re-administration of Pranlukast, the clinical symptoms disappeared within a few days
and pulmonary function improved within 4 weeks. Eosinophils in the induced sputum almost completely disap-
peared for 4 weeks. The sputum ECP and eotaxin before and 4 weeks after the re-administration of Pranlukast
changed from 700 μgl to 192 μgl, and 69.9 pgml to 30.6 pgml, respectively. After 8 weeks, no sputum in-
duction was found.
Conclusions: The clinical difference between these two similar antagonists may be caused by the time differ-
ence relating to when and how often each drug is administered, suggesting the existence of the lunchtime dip.
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INTRODUCTION
Cysteinyl leukotriene (CysLT) receptor antagonists
are defined as drugs for the long-term control of
asthma in the Guide for Asthma Management and
Prevention published by the Global Institute for
Asthma (GINA)1 and in the Asthma Prevention and
Management Guidelines 2003 (JGL).2 At present, the
CysLT1 receptor antagonists used in Japan are Pran-
lukast , Montelukast and Zafirlukast . These three
drugs show almost the same levels of CysLT1 recep-
tor antagonism.3 Although no significant differences
in clinical effects were found in a comparative study
of Pranlukast and Montelukast,4 both drugs differ in
the type of the drug form; a capsule or a small tablet,
and the daily administrative time ; when and how
often each drug is taken. In daily use, the recom-
mended daily dose of Pranlukast for adults is 4 cap-
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sules (450 mgday), taken twice daily (after breakfast
and dinner), while the recommended daily dose of
Montelukast is 10 mgday taken once prior to sleep-
ing.
Drug compliance is highly dependent on the drug
form and the administration time, especially in eld-
erly asthmatic patients. The author has often encoun-
tered patients who found it difficult to take capsules
or wished to decrease the number of capsules they
were required to take, often resulting in an adminis-
trative change from Pranlukast to Montelukast. How-
ever, I have also experienced not a few patients who
then requested re-administration of Pranlukast, due
to aggravated subjective symptoms which developed
after the change of drugs. The case report given be-
low involves one such patient.
In this case report , in addition to evaluating the
changes in clinical symptoms and pulmonary func-
tions, I also investigated the eosinophil count, eosino-
phil cationic protein (ECP) and eotaxin in the hyper-
tonic saline-induced sputum before and after the re-
administration of Pranlukast from Montelukast.
CLINICAL SUMMARY
The patient was a 70-year-old male with non-atopic
bronchial asthma who visited our department in Feb-
ruary 2001 and was given Beclomethasone dipropion-
ate (BDP), a steroid inhalant, at a dose of 800 μgday,
based on Step 3 of the“Severity Criteria for Bron-
chial Asthma”developed by the Japanese Society of
Allergy.2 In May 2002, his asthma was under effective
control using 400 μgday of Budesonide Turbu-
halerⓇ (BUD-TH), a steroid inhaler, 100 mgday of
theophylline, 2 mgday of a Tulobuterol patch, and
450mgday of Pranlukast . In November 2002, be-
cause of his good stable asthmatic condition, the pa-
tient requested a decrease in the number of oral drug
capsules. Therefore, 4 capsules of Pranlukast were
changed into one tablet of Montelukast at bedtime.
For several weeks after the change , his asthmatic
condition showed no remarkable change, and then
the amount of sputum and cough gradually increased
in the daytime, in particular at lunchtime. In June
2004, he had a moderate asthma attack and was ad-
mitted to our hospital. After admission, BUD-TH was
increased to 600 μgday and wheezing and breathing
difficulty quickly improved, but the sputum associ-
ated with cough persisted during the daytime. Again
based on the patient’s request, Montelukast was re-
placed with Pranlukast in September 2004. A few
days afterwards, the sputum associated with cough at
daytime disappeared spontaneously and completely.
According to his daily asthma diary and a detailed in-
terview with his family, his drug compliance was con-
firmed as almost 100% over this course. His clinical
course for the two months is shown in Figure 1.
PATHOLOGICAL FINDINGS
In order to investigate the relationship between the
changes of his asthmatic condition and eosinophilic
inflammation in his peripheral airway , the induced
sputum tests were performed before and after the
change from Montelukast to Pranlukast. Prior to per-
forming the each test , the purpose , methods and
risks of the test were explained to the patient in detail
each time, in accordance with the code of ethics at
our hospital which is based on the Declaration of Hel-
sinki of 1995 (as revised in Edinburgh 2000). After in-
formed consent was obtained , the test was con-
ducted. The patient inhaled a 10% salt solution for 15
minutes using an ultrasonic nebulizer , and the in-
duced sputum was collected by a deep cough after
gargling. The saliva component was removed from
the collected sputum, and a smear preparation of the
viscous sputum component was made. This was then
stained with Wright-Giemsa stain. The mean number
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Eotaxin (pg/ml)ECP (μg/l)EoTime Point
69.9700(＋)Before re-administration of Pranlukast
30.6192(−)4 weeks later
no sputum induction8 weeks later
Abbreviations: Eo = eosinophil, ECP = eosinophil cationic protein
Table 1 Results of hypertonic saline-induced sputum tests
Criteria for Eosinophils
JudgmentMean counts of eosinophils in 5 HPF (X)
(−)X＜1
(＋)1＜or＝X＜10
(2＋)10＜or＝X＜20
(3＋)20＜or＝X
V
・
25/H (L/sec/m)V
・
25 (L/sec)V
・
50 (L/sec)%FEV1.0 (%)%FVC (%)%VC (%)
0.46 0.681.1172.955.170.62002.4
2002.11 change from Pranlukast to Montelukast
0.27 0.391.0268.457.872.42003.4
0.36 0.540.8364.058.362.72003.10
0.44 0.660.5769.653.561.72004.4
2004.6 dose of BUD-TH increased from 400 μg/day to 600 μg/day　　　　　　　　
0.44 0.640.8861.342.846.62004.9 (before change of drugs）
2004.9 change back to Pranlukast from Montelukast
0.50 0.740.8665.449.149.14 weeks later
0.50 0.731.0671.450.151.28 weeks later
Abbreviations: VC＝vital capacity, FVC＝forced vital capacity, FEV 1.0＝forced expiratory volume during 1 second
Table 2 Changes in pulmonary function test data with time
of eosinophils per 5 microscopic views (×400) was ob-
tained, based on the following criteria: per 5 views,
one or less eosinophil, (−); one to less than 10, (+); 10
to less than 20, (2+); 20 or more, (3+). The sputum
ECP and eotaxin levels were determined according to
the method of Motojima et al..5 Induced sputum was
kept at 4℃ from the time of collection to sample
preparation; samples were always prepared within 6
hours. The sputum ECP and eotaxin levels were de-
termined using an ECP FEIA kit (Pharmacia & Up-
john Diagnostics AS, Uppsala, Sweden) and an eo-
taxin ELISA kit (R&D Systems, MN, USA), respec-
tively. The mean eosinophil count and the ECP and
eotaxin levels in induced sputum immediately before,
and 4 and 8 weeks after re-administration of Pranlu-
kast are shown in Table 1. Pulmonary function data
from April 2002, i.e., before the initial change from
Pranlukast to Montelukast , to November 2004 are
shown in Table 2. All pulmonary function data were
measured between 11 a.m. and noon. Four weeks af-
ter the change from Montelukast to Pranlukast, the
eosinophil count in induced sputum was negative ,
and sputum ECP and eotaxin were markedly de-
creased. Furthermore, 8 weeks after this change, no
sputum could be induced. The pulmonary function
values were aggravated after the change from Pranlu-
kast to Montelukast and then improved after re-
administration of Pranlukast (Table 2).
DISCUSSION
Pranlukast and Montelukast are CysLT1 receptor an-
tagonists with almost the same pharmacological anti-
LT activity , although their administered doses and
drug forms are different.3,4 In the present case, the
patient experienced subjective asthma symptoms af-
ter switching from Pranlukast to Montelukast which
then improved after a change back to Pranlukast .
This was objectively proved based on the results from
the pulmonary function data. Collectively, the objec-
tive and subjective results suggest that Pranlukast
and Montelukast had a different clinical effect in this
patient.
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Fig. 2 Time-course change of blood concentration (outline)
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In addition to exerting strong LT receptor antago-
nism, CysLT1 receptor antagonists suppress eosino-
phil activation, leading to reduction of serum ECP,6,7
and inhibit cellar infiltration of inflammatory cells in
bronchial mucosa,8 as well as eosinophilic migration
through suppression of eotaxin, an eosinophilic mi-
gration factor . 9 However , a direct comparison of
eosinophil suppression has not been performed for
Montelukast and Pranlukast. We therefore found the
different suppression effects of Montelukast and
Pranlukast in the present case to be of particular in-
terest, and we examined the eosinophilic conditions
of the peripheral airway before and after the change
of drugs , using the induced-sputum method de-
scribed above. It is generally accepted that hyper-
tonic saline-induced sputum in this study can be used
to determine the main conditions of the peripheral
airway,10,11 and this method has recently received at-
tention due to its clinical applicability; it is easily per-
formed for outpatients and shows good reproducibil-
ity.12,13 In the present case, markedly reduced levels
of eosinophils, ECP and eotaxin were found in the in-
duced sputum after re-administration of Pranlukast,
compared to the levels during treatment with Mon-
telukast, suggesting that Pranlukast is able to reduce
peripheral airway eosinophilic inflammation and im-
plying that there may be a clinical difference between
Pranlukast and Montelukast in this respect.
In trials in normal volunteers in Japan, the time to
reach the peak Pranlukast concentration in blood was
5.2 ± 1.1 hr and the half-life (t12) was 1.15 ± 0.13 hr,
suggesting that Pranlukast administration twice a day
is necessary to maintain an effective blood concentra-
tion of 30 ngml.14 On the contrary, the peak blood
Montelukast concentration was reached in 3.9 ± 1.5
hr and the t12 was 4.57 ± 0.39 hr, suggesting that
Montelukast repeat administration at bedtime allows
a sufficient blood concentration to be maintained until
noon the next day.15 However, pharmacokinetics can
differ on an individual basis, and in the present case
the patient showed asthma symptoms before noon,
suggesting that the blood concentration of Montelu-
kast may have already decreased below an effective
concentration before noon. As shown in Figure 2, in
Pranlukast-treated patients the drug concentration in
the blood remained almost at its peak concentration
around noon. Hence, there may be significant differ-
ences in the blood concentrations of Pranlukast and
Montelukast at this time of day.
Aggravated asthma symptoms that occur early in
the morning are considered to be caused by a morn-
ing“dip”, and Montelukast is administered at bed-
time to suppress such symptoms. However , at the
2004 American College of Chest Physician (ACCP)
Annual Congress, Medarov gave a very interesting
presentation,16 in which it was reported that the pul-
monary function data of 4800 asthma patients showed
a lunch-time dip around noon, i.e., the lowest pulmo-
nary function occurred at this time, as well as a morn-
ing dip. In the present case, the patient also showed
aggravated symptoms with low pulmonary function
before noon during treatment with Montelukast, con-
sistent with data from Medarov. Re-administration of
Pranlukast twice a day improved the symptoms of the
patient, and therefore I concluded that a difference in
blood concentration between Pranlukast and Mon-
telukast may be one of the reasons for the clinical dif-
ference between the two drugs in the patient.
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